Abstract
Objective: Knee osteoarthritis is a common disabling chronic disease globally. Many pharmacological agents have been used efficiently in treatment of knee osteoarthritis. This study aims to evaluate metformin and serratiopeptidase together in treatment and stop of osteoarthritis progression by different mechanisms. Methods: Present study was a randomized clinical trial study conducted in Al-Kindi teaching hospital through the period from 1st January to 30th of May, 2017 on two groups of 80 osteoarthritis patients (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets and serratiopeptidase 20 mg oral tablets). Parameters of two groups were compared with those of 40 normal healthy controls. Results: Patients in group II showed a highly significant reduction in pain scores post-treatment (p<0.001). Tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1ß) and interleukin 8 (IL-8) levels were significantly lowered among patients in group II treatment (p<0.001). Lower inflammatory parameters levels were observed among healthy controls and the parameters levels of group II patients were lower than those of group I patients. Conclusion: Metformin and serratiopeptidase regimen was efficient and safe in the treatment of knee osteoarthritis.
Highlights
Knee osteoarthritis (OA) is a common disabling chronic disease globally [1]
This study included 80 knee OA patients, 42.5% of patients in groups of osteoarthritis patients (group I) were in age group ≥60 y while 47.5% of patients in group II were in age group ≥60 y
TNF-α was significantly lowered among OA patients in both study groups post-treatment (p
Summary
Knee osteoarthritis (OA) is a common disabling chronic disease globally [1]. OA is a disorder of synovial joints cased characterized pathologically by damaging of articular cartilage, increased load, thickening of the capsule, subchondral bone changes and osteophytosis [2]. The obesity is a major epidemic all over the world and it is greatly linked to OA [3] and its effect on OA is multi-factorial [4]. The obesity is responsible on initiating the mechanical effects which lead to knee joint damage by high load, muscular weakness and biomechanical changes [5], in addition to the effect of metabolic factors [6] like lipids and humoral mediators [7]. The symptoms of knee OA are commonly pain, stiffness, tenderness and swelling [8].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
